An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.
You may also be interested in...
Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch
Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.
Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch
Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.
Effient Approval Shows Mark Of FDA Controls
Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.